Haisco Pharmaceutical Wins Approval for New Migraine Drug Trial
Stock News
Aug 06
Haisco Pharmaceutical Group Co.,Ltd. (002653.SZ) has announced that it recently received a Drug Clinical Trial Approval Notice from the National Medical Products Administration for its innovative drug, HSK51155 tablets.
HSK51155 is an orally administered small-molecule analgesic drug independently developed by the company with its own intellectual property rights. It is clinically intended for the treatment of migraines.
The drug aims to effectively control pain while reducing the occurrence of adverse reactions and avoiding the risk of addiction, offering patients a safer and more effective option for pain management.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.